All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% previous systemic treatment (%) previous systemic treatment NO (%) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - 2nd line (L2), immune chekpoint inhibitors vs. anti-CTLA-4, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.04 [0.83; 1.30]
0.80 [0.65 ; 0.98 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 67% 2,379 low not evaluable deaths (OS) (extension)detailed results KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.68 [0.57 ; 0.81 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable PFS (extension)detailed results KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.61 [0.53 ; 0.70 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.65 [0.51 ; 0.84 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 67% 1,839 moderate not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
1.19 [0.86 ; 1.63 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.49 [0.25; 0.97]
1.78 [0.78 ; 4.03 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 91% 2,379 moderate not evaluable AE (any grade)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.96 [0.55; 7.07]
1.96 [0.55 ; 7.07 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.99 [0.66; 1.47]
0.99 [0.66 ; 1.47 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.65 [0.46 ; 0.92 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.99 [1.17; 3.41]
1.74 [1.24 ; 2.44 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 64% 2,304 moderate not evaluable TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.17 [0.68; 2.01]
1.22 [0.66 ; 2.26 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 87% 2,304 moderate not evaluable TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.78 [0.43 ; 7.37 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.28 [0.72 ; 2.27 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 74% 1,793 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
2.23 [1.51 ; 3.30 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.63 [0.16 ; 16.15 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,237 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.16 [0.16 ; 8.29 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.58 [0.22; 1.50]
0.55 [0.19 ; 1.58 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 80% 2,304 low not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.85 [0.06 ; 55.43 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.30; 2.12]
1.01 [0.53 ; 1.93 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 48% 2,304 low not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.27 [0.07; 1.01]
0.84 [0.10 ; 6.86 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 86% 1,237 low not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.64 [0.17 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.74 [0.34; 1.61]
1.23 [0.51 ; 2.94 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 73% 1,237 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
2.64 [0.90 ; 7.72 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 0% 2,304 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2.78 [0.15; 52.88]
2.78 [0.15 ; 52.88 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
6.01 [0.30 ; 120.38 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.05; 2.45]
0.89 [0.40 ; 1.97 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 0% 2,304 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
1.26 [0.22 ; 7.29 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 0% 2,304 low not evaluable Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
1.10 [0.19 ; 6.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 40% 2,304 low not evaluable Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.32 [0.26 ; 6.75 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 45% 2,304 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.94 [0.15 ; 5.80 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.63 [0.29 ; 9.28 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.72 [0.08 ; 6.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.91 [0.21 ; 3.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 0% 2,304 low not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.73 [0.20; 14.97]
1.87 [0.57 ; 6.11 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 0% 2,304 low not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.56 [0.33; 7.34]
1.46 [0.58 ; 3.68 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,237 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.72 [0.08 ; 6.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Vitiligo TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.01; 17.42]
0.34 [0.01 ; 17.42 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.37 [0.11 ; 17.90 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
1.03 [0.21 ; 5.19 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.95 [0.30; 3.03]
0.95 [0.30 ; 3.03 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Constipation AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.07; 1.70]
0.34 [0.07 ; 1.70 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Cough AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.69 [0.02 ; 20.65 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
1.03 [0.21 ; 5.19 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.83 [0.34; 2.05]
0.83 [0.34 ; 2.05 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.96 [0.34; 2.73]
0.96 [0.34 ; 2.73 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Fatigue AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.71 [0.31; 1.62]
0.71 [0.31 ; 1.62 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Headache AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.45 [0.10; 2.06]
0.45 [0.10 ; 2.06 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Nausea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.68 [0.17; 2.78]
0.68 [0.17 ; 2.78 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Pyrexia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.38 [0.06 ; 30.82 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable Vomiting AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.20; 3.14]
0.80 [0.20 ; 3.14 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1 0% 511 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-29 05:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 286,69,129
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
